Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Three Patent Applications Related to RNAi: Dec 21, 2006

Title: Methods of Inhibiting VEGF-C
Number: 7,150,970
Filed: Aug. 1, 2005
Lead Inventor: Douglas Trask, University of Iowa
The invention, the patent’s abstract states, “provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for VEGF-C, and further provides methods of reducing expression of VEGF-C in cells (e.g., cancer cells).”

Title: Transgenic Plant-Derived siRNAs for Suppression of Influenza Virus in Mammalian Cells
Number: 20060282921
Filed: April 10, 2006
Lead Inventor: Eric Lam, University of Hong Kong
The invention “provides plant-derived agents to interfere with the nonstructural NS1 gene from the influenza A virus subtype H1N1,” the patent application’s abstract states. “More particularly, the siRNAs that exhibit strong inhibitory activity towards NS1, which effectively suppress replication of the influenza virus in mammalian cells. The invention further provides methods for production of siRNAs for the suppression of a broad range of influenza viral subtypes with sequence homologies.”

Title: Modification of Apolipoprotein A Expression
Number: 20060281698
Filed: June 2, 2004 PCT Filed: June 2, 2004
Lead Inventor: Rosanne Crooke, Isis Pharmaceuticals
According to the patent application’s abstract, the invention comprises “compounds, compositions, and methods … for modulating the expression of apolipoprotein A. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein A. Methods of using these compounds for modulation of apolipoprotein A expression and for diagnosis and treatment of disease associated with expression of apolipoprotein A are provided.”

Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Number: 20060281175
Filed: Aug. 11, 2006
Lead Inventor: James McSwiggen, Sirna Therapeutics
The invention ”concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications,” the patent application’s abstract states. “Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.